CAS 1370651-20-9

Ensartinib

CAS : 1370651-20-9

Ensartinib

Degré de pureté : ≥98%

Masse moléculaire : 561.44g/mol

Ref: 54-BUP21136

Ensartinib(X-396)

CAS : 1370651-20-9

Formule : C₂₆H₂₇Cl₂FN₆O₃

Masse moléculaire : 561.44

Ref: 4Z-E-165001

Ensartinib

CAS : 1370651-20-9

Ensartinib (X-396) is a potent and orally active dual ALK/MET inhibitor for the treatment of ALK-positive non-small cell lung cancer (NSCLC).

Formule : C₂₆H₂₇Cl₂FN₆O₃

Degré de pureté : 99.92%

Couleur et forme : Solid

Masse moléculaire : 561.44

Ref: TM-T37585

Ensartinib-13C2-d6

CAS : 1370651-20-9, 2137030-98-7

Formule : C₂₄₁₃C₂H₂₁D₆Cl₂FN₆O₃

Masse moléculaire : 569.46

Ref: 4Z-E-165002

Ensartinib

CAS : 1370651-20-9

Ensartinib is a small-molecule inhibitor of anaplastic lymphoma kinase (ALK), which is a receptor tyrosine kinase. This product is derived from chemical synthesis and classified as a targeted cancer therapy. Ensartinib’s mode of action involves the selective inhibition of ALK phosphorylation, which blocks downstream signaling pathways involved in cell proliferation and survival.

Formule : C₂₆H₂₇Cl₂FN₆O₃

Degré de pureté : Min. 95%

Masse moléculaire : 561.4 g/mol

Ref: 3D-VEC65120